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Abstract 
Our object was to develop a bone substitute coated with fibroblast growth factor-2 
(FGF-2) that subsequently releases FGF-2.  We investigated the use of our system of 
bone substitutes to induce bone formation.  Hydroxyapatite ceramic buttons 
(HAP-CBs) were coated with FGF-2 by precipitation in supersaturated calcium 
phosphate solution.  HAP-CBs were coated with high or low doses of FGF-2, denoted 
as FGF-H and FGF-L.  The release of FGF-2 from FGF-H and FGF-L was evaluated 
using its release profile and bioactivity.  The efficacy of the subsequent bone formation 
was quantified using rats with round-shaped bone defects (5 mm in diameter) of the 
right parietal bone.  Group 1 was treated only with HAP-CBs, Group 2 with HAP-CBs 
and drops of FGF-2 solution, Group 3 with FGF-L, and Group 4 with FGF-H.  To 
detect the release of FGF-2 in vivo, the expression of bone morphogenic protein-2 
(BMP-2) was measured in the defective bone tissue.  FGF-2 was released in vitro from 
FGF-H and FGF-L and maintained its bioactivity.  Rats treated with FGF-L showed 
better bone formation than rats from the other groups.  BMP-2 expression was detected 
in the defective bone tissues of Group 3 at 14 days, which might indicate in vivo FGF-2 
release during this period.  A specific FGF-2 concentration may be needed for bone 
formation, and our system can release FGF-2 at adequate concentrations to induce bone 
formation.   
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Introduction 
Recently, many studies have reported that certain proteins, such as fibroblast 
growth factor-2 (FGF-2) [1-3], transforming growth factor-β (TGF-β) [4], and bone 
morphogenetic proteins (BMPs, which belong to the TGF-β superfamily) [5-8], can 
stimulate bone formation.  In their use as clinical medicines, safety and quality are 
necessary conditions for using these proteins as drugs.  FGF-2 is one of the most 
promising and practical options because FGF-2 has already been approved as a clinical 
pharmaceutical in Japan and is commercially available.  When cytokines such as 
FGF-2 are administered in vivo, a large proportion of the applied cytokines are rendered 
inactive due to degradation or non-specific binding [5,9].  In general, the delivery 
system cannot maintain the in vivo effects of FGF-2 for very long.  Therefore, a new 
delivery system is needed for the administration of FGF-2 to be useful [3].   
The ability to hold and release various kinds of proteins, including FGF-2, has 
been studied [10,11].  In studies using cytochrome C (cyt C) as a harmless dummy 
protein, cyt C was effectively coated to a hydroxyapatite (HAP) ceramic, forming a cyt 
C/calcium phosphate composite layer in supersaturated calcium phosphate solutions 
prepared by mixing several types of infusion fluids [10].  Because the molecular 
weight and isoelectric focusing point of FGF-2 are analogous to those of cyt C, an 
FGF-2/calcium phosphate composite layer would be expected to form on HAP ceramic 
[11] and then be slowly released from it.  
HAP has already been applied to various clinically approved bone substitutes, 
such as the burr-hole buttons that are used to repair cranial defects.  HAP causes 
minimal foreign-body reactions and acts as an osteoconductive material, binding easily 
to bone [12,13].  Therefore, HAP may be a good material to repair bone defects such 
as in cranioplasties, and it may also be a suitable substrate for binding FGF-2.   
In this study, an FGF-2/calcium phosphate composite layer was formed on a 
HAP ceramic button (HAP-CB) using clinically approved pharmaceutical solutions and 
FGF-2.  The amount of FGF-2 released and the biological activity of the resulting 
material were studied to confirm its abilities both in vitro and in vivo. 
 
 
 
Materials & Methods 
Preparation of HAP-CB 
 Pure, stoichiometric HAP powder was supplemented with 3% (wt) polyvinyl 
alcohol and 1% (wt) polyethylene glycol and sieved to select only particles under 75 µm 
in size and then formed into disks at 98 MPa and sintered at 1150°C for one hour.  The 
resulting shape of HAP-CB is shown in Figure 1, with a surface area of 15.94 mm2 and 
a mean thickness of 1.00 mm per button.  The HAP-CB was designed for a round 
cranial bone defect 5 mm in diameter, and its sides were cut bilaterally to permit bone 
formation into the space that was created by cutting. 
 
FGF-2 solution  
 An FGF-2 solution was prepared by dissolving FGF-2 (Fiblast®, Kaken 
Pharmaceuticals, Japan) in a sterilized physiological salt solution at the final 
concentration of 100 µg/mL.  Fiblast is a pharmaceutical human recombinant FGF-2 
containing an undisclosed amount of sucrose, ethylene diamine tetraacetic acid, and a 
pH adjustment agent. 
 Preparation of the other solutions 
  A calcium-containing solution, a phosphate-containing solution, and an 
alkalinizer (Table 1) were prepared by dissolving reagent-grade KCl, CH3COONa・
3H2O, NaHCO3, KH2PO4, Xylitol (Wako Pure Chemical Industry Ltd., Japan), NaCl, 
CaCl2・2H2O, K2HPO4・3H2O, and MgCl2・6H2O (Nacalai Tesque Co., Japan) in 
ultra-pure water.  These solutions are equivalent in their chemical composition to the 
clinically available infusion fluids.  The calcium-containing solution corresponds to 
Ringer’s solution (Otsuka Pharmaceutical Co., Ltd., Japan), including 147 mM Na+, 
4.00 mM K+, 2.25 mM Ca2+, and 157 mM Cl- at pH 6.43.  The phosphate-containing 
solution corresponds to Klinisalz® B (I’rom Pharmaceutical Co., Ltd., Japan) and 
contains 45.0 mM Na+, 25.0 mM K+, 2.50 mM Mg2+, 45.0 mM Cl-, 10.0 mM H2PO4-, 
20.0 mM CH3COO-, and 333 mM Xylitol at pH 5.87.  The alkalinizer is a NaHCO3 
solution corresponding to Bifil® (AJINOMOTO PHARMA Co., Ltd., Japan) and 
contains 166 mM Na+, and 166 mM HCO3- at pH 8.28.   
 
Formation of a calcium phosphate composite 
The above-mentioned solutions were mixed to prepare supersaturated calcium 
phosphate solutions that included the FGF-2 solution.  The supersaturated calcium 
phosphate solution with FGF-2 was filtered using a membrane with a pore size of 0.22 
µm.  HAP-CBs were immersed in 2 mL of the supersaturated calcium phosphate 
solution for 24 hours at 25°C.  Two conditions were chosen for the FGF-2 coating with 
precipitation: a high-dose FGF-2 coating, which was named “FGF-H,” and a low dose 
FGF-2 coating, which was named “FGF-L.”  An HAP-CB was also prepared under 
FGF-H conditions but without FGF-2, and this condition was named “HAP-N”.  All of 
the HAP-CBs were used immediately after washing with 2 mL of phosphate-buffered 
saline (PBS).  The surfaces of the HAP-CB, FGF-L, FGF-H, and HAP-N were 
observed using a scanning electron microscope (SEM; JSM-5500LV, JEOL Ltd., Japan).  
 
in vitro FGF-2 release assay 
 FGF-L and FGF-H buttons were immersed in 2 mL of Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco-BRL, Grand Island, NY) without fetal bovine serum 
(FBS) and allowed to sit at 37°C for up to 16 days.  DMEM was used to simulate the 
in vivo setting because it contains various minerals at concentrations close to those 
found in the body fluid.  At each measured time point, 0.15 mL of DMEM was added 
after collecting 0.15 mL of sample from each well.  The FGF- 2 concentration in these 
samples was measured with an ELISA (human Fibroblast Growth Factor-2 ELISA kit, 
Calbiochem, EMD bioscience, CA), and the amounts of the released FGF-2 were 
calculated. 
 
in vitro biological activity induced by FGF-2 
 BHK-21 cells (RIKEN BioResouce Center, Tsukuba, Japan), which are 
fibroblastic cells derived from hamster and can respond to FGF-2, were used to evaluate 
the biological activity of FGF-2.  MG-63 cells (RIKEN BioResouce Center), which are 
osteoblastic cells derived from humans, were used to evaluate the FGF-2 concentrations 
for bone formation.  The BHK-21 cells were maintained in DMEM containing 10% 
FBS, and the MG-63 cells in modified Eagle’s medium (MEM; Gibco-BRL) with 10% 
FBS.  Cells (1 x 104 / well) were seeded on 24-well culture plates.  In some wells, 
FGF-2 was added to the medium at each concentration, and FGF-H or FGF-L buttons 
were placed on the bottom of the other wells.  The cells were cultured for three days at 
37°C in a humidified CO2 incubator with 1 mL of medium without FBS.  After this 
step, the cells were detached via a trypsin treatment and counted with a counting 
chamber slide.  The wells grown with 10% FBS were used as a positive control.  In 
some wells, bone morphogenetic protein-2 (BMP-2) expression was evaluated by the 
Mini Opticon real-time PCR system (Bio-Rad Laboratories Inc.). 
 
Animal experiments 
 During all of the experiments that were approved by the Institutional Animal 
Care and Use Committee, the animals were housed and handled in accordance with the 
guidelines of the National Institutes of Health.  Seven- to eight-week-old male Wister 
rats were purchased (Japan Crea Co., Ltd., Japan).  Under anesthesia, a round 
craniotomy (5 mm in diameter) was drilled into the right parietal bone.  The rats were 
divided into four treatment groups.  In Group 1, the cranioplasty was performed with 
HAP-N buttons alone.  In Group 2, the cranioplasty was performed with HAP-N 
buttons with drops of the FGF-2 solution containing 500 ng of FGF-2 applied directly to 
the HAP-N buttons.  Groups 3 and 4 were treated with FGF-L buttons and FGF-H 
buttons, respectively.  Rats were sacrificed at two, four, and eight weeks after the 
procedures, and the skull bones were removed together with the defects.  The samples 
were fixed in 10% formaldehyde in PBS for four days and then demineralized in 10% 
ethylene diamune tetraacetic acid solution at 4°C for three days, embedded in paraffin, 
and cut into 10-µm-thick sections.  The samples were cut into the center of the skull 
defect, or at the nearest possible site, at a right angle across the lengthwise axis of the 
HAP-CB (Fig. 2).  These sections were stained with hematoxylin and eosin and were 
viewed using an IX71 microscope system equipped with the DP-Controller imaging 
software (Olympus, Japan).  In cranial bone healing, it is reported that bone formation 
occurs in the periphery of the bone defect [14] and on the dural membrane side [15].  
Bone formation was quantified by measuring the length of the new bone extension into 
the inside of the bone defect and the thickness of the edges of the bone defect using the 
IX71 microscope system (Olympus).  In some rats, the tissue inside of the bone defects 
was removed and homogenized.  Total RNA was isolated, and cDNA was synthesized.  
The expression levels of BMP-2, alkaline phosphatase (ALP), and osteocalcin (OC) 
were evaluated with the Mini Opticon real-time PCR system (Bio-Rad Laboratories). 
 
The detection of Bmp-2, ALP, and OC expression with real-time PCR 
       The in vitro cell samples were washed three times with PBS.  The in vivo 
tissue samples were homogenized and centrifuged, and the supernatant was used to 
extract RNA.  Total RNA was extracted from some samples with an RNA extraction 
kit (QIAGEN).  One microgram of total RNA was reverse transcribed in a buffer 
containing 1 µL of oligo-dT primers (2.5 µM), 250 µM deoxynucleotides, 10 U RNasin 
(Promega), and 100 U Superscript II (Gibco-BRL).  This mixture was incubated for 75 
minutes at 42°C and for 5 minutes at 75°C.  The expression levels of BMP-2, ALP, OC, 
and GAPDH were detected using the following primers: forward primer 
5’-AAGGCACCCTTTGTATGTGG-3’ and reverse primer 
5’-CATGCCTTAGGGATTTTGGA-3’ for BMP-2 [16]; forward primer 
5’-GAGCAGGAACAGAAGTTTGC-3’ and reverse primer 
5’-GTTGCAGGGTCTGGAGAGTA-3’ for ALP [16]; forward primer 
5’-AGCTCAACCCCAATTGTGAC-3’ and reverse primer 
5’-AGCTGTGCCGTCCATACTTT-3’ for OC [16]; and forward primer 
5’-AACTCCCATTCCTCCACCTT-3’ and reverse primer 
5’-GAGGGCCTCTCTCTTGCTCT-3’ for GAPDH [16].  Each primer (12.5 pM) was 
added to a solution containing 12.5 µL of iQ SYBR green supermix (Bio-Rad 
Laboratories) along with 0.5 µL of template sample (final volume, 25 µL).  The Mini 
Opticon real-time PCR system (Bio-Rad Laboratories Inc., Hercules, CA) was used.  
The expression levels of BMP-2, ALP, and OC were indicated as the delta cycle times 
(∆ cycle(t)).  Some of the BMP-2 expression levels were reported as the fold increase 
(∆-∆ C(t)), in which values normalized to GAPDH expression were compared with the 
BMP-2 expression in HAP-N. 
 
Statistical analysis 
 The experimental results are expressed as the mean ± the standard deviation.  
All data were analyzed using Student’s t-test, and probability values less than 0.05 were 
considered to be statistically significant.   
Results 
SEM observation 
       Each HAP grain was covered with fine particulate precipitations (Fig. 3B, 3C, 
3D).  No particle with a diameter of more than 1 mm was observed at the surface of 
the HAP, which indicated that homogenous nucleation did not occur in the 
supersaturated calcium phosphate solution. 
 
Evaluation of the cell responses to soluble FGF-2 
 BHK-21 cells were incubated for three days in each concentration of FGF-2 
and counted.  The measured values were indicated as the average and standard 
deviation of three independent experiments.  BHK-21 cell proliferation was responsive 
to FGF-2 concentrations between 1 and 100 ng/mL (Fig. 4A).  MG-63 cells were 
incubated for three days in each concentration of FGF-2.  MG-63 cells proliferated 
better at FGF-2 concentrations between 1 and 10 ng/mL (Fig. 4B).   
      To look at gene expression levels, BMP-2 expression was evaluated using 
BHK-21 and MG-63 cells.  BMP-2 expression was induced in osteoblasts through the 
administration of FGF-2 [17,18].  BMP-2 expression was indicated as fold increase 
(∆-∆ C(t)), in which values normalized to GAPDH expression were compared with the 
BMP-2 expression levels in wells with 0 ng/mL FGF-2.  BMP-2 expression in cells 
cultured with 10% FBS was taken as the positive control because FBS includes several 
types of growth factors.  The measured values were indicated as the average and 
standard deviation of three independent experiments.  BMP-2 expression in MG-63 
cells peaked when they were cultured with concentrations of FGF-2 between 3 and 10 
ng/mL, and it decreased at concentrations over 30 ng/mL (Fig. 4C).   BMP-2 
expression did not change in BHK-21 cells, likely because these cells may be 
fibroblasts.  An adequate concentration of FGF-2 may be needed to activate 
osteoblasts such as MG-63 cells.   
 
in vitro release of FGF-2 from FGF-L or FGF-H buttons 
 FGF-L and FGF-H buttons were immersed in 2 mL of DMEM without FBS. 
FGF-2-release from the FGF-L and FGF-H buttons was observed over time (Fig. 5).  
The measured values were indicated as the average and standard deviation of three 
independent experiments.  The FGF-H buttons released approximately 26 ng/mL of 
FGF-2, and the FGF-L buttons released around 5.8 ng/mL of FGF-2.  The FGF-L and 
FGF-H buttons continued to release FGF-2 over 16 days. 
 
in vitro biological activity of the released FGF-2  
      The biological activity of FGF-2 was evaluated by monitoring the proliferation 
of BHK-21 cells.  The measured values were indicated as the average and standard 
deviation of three independent experiments.  The cell counts in the wells that included 
the FGF-H buttons were higher than those in the wells that included the FGF-L buttons 
(Fig. 6A).  Because the FGF-H buttons could release more FGF-2 than the FGF-L 
buttons, the difference in the observed cell proliferation is reasonable.  These findings 
indicate that the FGF-2 coated onto and released from the HAP-CBs maintained its 
biological activity.  In MG-63 cells, the cell counts in the wells that included the 
FGF-H buttons were lower than those in wells with the FGF-L buttons (Fig. 6B).  The 
dose of FGF-2 released from the FGF-H buttons might be too high to stimulate these 
osteoblast cells.   
    BMP-2 expression was evaluated in samples incubated with HAP-N, FGF-L, or 
FGF-H buttons.  The measured values were indicated as the average and standard 
deviation of three independent experiments.  When BHK-21 cells were incubated with 
HAP-N, FGF-L, or FGF-H buttons, there was no difference in BMP-2 expression (Fig. 
6C).  When MG-63 cells were incubated with HAP-N, FGF-L, or FGF-H buttons, the 
FGF-L buttons increased the expression of BMP-2 more than the other treatments (Fig. 
6C).  These findings indicate that the FGF-L buttons may release an effective 
concentration of FGF-2 to stimulate osteoblast cells.  Thus, we predict that FGF-L 
buttons would be more effective for in vivo bone formation.  
 
in vivo bone formation 
 Eighteen rats were in each group and six rats were sacrificed at two, four, and 
eight weeks after the craniotomy procedures.  We observed new bone formation as 
extension into the open space on both sides of HAP-CB (indicated by the ‘extension’ 
value in Figure 2 and 7A) and increased thickness in the space between the edge of the 
bone defect and the dura membrane (indicated by the ‘thickness’ value in Figure 2 and 
7B).  Figures 7A and 7B show the histological sections from Group 3 rats treated with 
FGF-L and 7C shows rats from Group 1 treated with HAP-N.  In Group 3, which was 
treated with the FGF-L buttons, bone formation was enhanced significantly more than 
that in Groups 1 or 2 (Fig. 8A and 8B).  There was no significant difference between 
Group 4 and Groups 1 or 2.  These findings suggest that only a regionally adequate 
concentration of released FGF-2 may be capable of stimulating for bone formation. 
 Two or four weeks after the procedures, some rats were sacrificed (n=3 in 
each group at each point), and the gene expression in the tissue of the bone defects was 
evaluated.  The measured values were indicated as the average and standard deviation 
of three independent experiments.  Increased BMP-2 expression levels were detected 
in Group 3, and BMP-2 expression was low in Groups 1, 2, and 4 at two weeks (Fig. 
9A).  Because osteoblasts express BMP-2 in response to an adequate concentration of 
FGF-2, the FGF-L buttons in Group 3 appeared to maintain an adequate in vivo release 
of FGF-2 for about two weeks.  At four weeks, BMP-2 expression decreased in Group 
3.  Increased expression of ALP and OC was observed in Group 3 at four weeks (Figs. 
9B and 9C).  These expression patterns suggested the progression of bone formation in 
Group 3. 
Discussion 
 In this study, we show that an FGF-2-releasing system can function in vivo to 
promote bone formation.  The enhancement of bone formation was observed in the 
periphery of the cranial bone defect and on the dural membrane side, as it was reported 
in other articles [14,15].  In many reports, polymer or collagen-gel devices have 
been used as in vivo delivery systems for cytokines [1-8].  However, there is no 
mechanical strength in these materials, and the cross-linkers that are used to make the 
gels may be toxic [3,4].  In this case, we tried to incorporate an FGF-2-releasing 
system into bone substitutes to repair the bone defects and to create a system that would 
use only government-approved medicines.  This FGF-2 releasing system was applied 
to cranioplasties, although a cranioplasty does not require mechanical strength.  Given 
that mechanical strength would be important for certain future applications, this 
releasing system could be applied to apatite as a substitute for its use in other operations 
without cranioplasty.  In addition, this release system could easily be modified for 
other applications.  Another advantage of this delivery system is that FGF-2 and other 
fluids are approved for use as medicines by the Japanese government, meaning that their 
safety is guaranteed.  Therefore, if the handling of this mixture of fluids and drugs is 
performed in accordance with “good manufacturer practice” regulations (GMP 
regulations), the quality and the safety of the final FGF-2-coated product can be 
guaranteed.  In our laboratory, we use a designated clean bench at which we can 
handle these materials in accordance with the GMP regulations to perform clinical 
studies. 
It has been reported that the releasing ability of apatite is rather low [19].  In 
our system, a few micrograms of FGF-2 were coated onto HAP-CBs, and about 52 ng 
(26 ng/mL x 2 mL/well) could be discharged in an in vitro releasing assay.  When 
considering a biologically effective concentration of FGF-2, 52 ng of released FGF-2 
might be enough to induce biological effects.  In our other studies, about 2-3 µg of 
FGF-2 was released from 3.06 cm2 of HAP disk with the FGF-2 coating in a 
physiological salt solution [10,11].  Calculating the surface area of HAP-CBs, the 
FGF-H buttons should have released about 150 ng of FGF-2.  Daculsi et al. reported 
that a dissolution-precipitation process of apatite occurred in settings with high calcium 
concentrations, such as in vivo [20].  In an in vitro releasing assay, the 
dissolution-precipitation process might occur, and the released FGF-2 might be 
reabsorbed into the apatite coating layer because the DMEM used in the assay contained 
a high dose of calcium.  This could make it difficult to estimate the available dose of 
the released FGF-2.  Although we wanted to evaluate the in vivo release of FGF-2, it 
appears to be more difficult for a few reasons: (1) there is an in vivo clearance system 
for FGF-2, and (2) the presence of heparan sulfate in the extracellular matrix could bind 
to FGF-2 and sequester it and/or enhance the activity of FGF-2 [21,22].  Instead, we 
used BMP-2 expression in osteoblast cells, which is induced by FGF-2, to evaluate the 
in vivo release of FGF-2.  Our data indicated that our system released FGF-2 in vivo 
over the course of two weeks and that there appeared to be an adequate in vivo 
concentration of FGF-2 for bone formation, consistent with the in vitro data [23,24].  
Some studies have reported that a high FGF concentration in vivo is not conducive to 
bone formation [25,26].  In our study, the FGF-H buttons, which released a high-dose 
of FGF-2, did not result in an increased level of bone formation compared to the FGF-L 
buttons.  Although the FGF-2 dose released from the FGF-H buttons might be just four 
or five times higher than that from the FGF-L buttons, there were significant differences 
in the bone formation between the FGF-H and FGF-L buttons.  These findings suggest 
that the FGF-2 concentration must be within a certain range to stimulate osteoblast cells.  
Strict control of the released FGF-2 dose might be needed for bone formation, as 
increasing the concentration of FGF-2 from 10 to 30 ng/mL resulted in a remarkable 
decrease in FGF-2-induced BMP-2 expression in vitro.  To strictly control the in vivo 
concentration of FGF-2, we think that one must be able to adjust the amount of coated 
FGF-2 on the HAP-CBs.   
When gel-releasing systems are used as delivery systems, it might be difficult 
to strictly control the amount of FGF-2 that is applied because it is easy for clinical 
doctors to apply too much medicine.  Some studies have reported that FGF-2 
gel-releasing systems were not effective because the concentration of released FGF-2 
was too high to stimulate osteoblast differentiation [25-27].  When considering the 
ability to manage the amount of applied FGF-2, our system may have an advantage over 
these other methods. 
 Enhanced bone formation after cranioplasty may be more meaningful for 
pediatric patients than for adult patients [28,29] because the failure of a cranioplasty can 
result in deformities of the cranium, a growing skull fracture, or the inconvenience of 
wearing headgear.  Just like the above-mentioned effects, enhanced bone formation 
may also play a large role in cervical operations, such as cervical anterior fusion or 
laminoplasty.  Although many instruments for cervical operations have been developed 
and are widely used, some doctors believe that cervical fixation by bone formation is 
more natural and preferential for some patients.   
 Generally, techniques for enhanced bone formation have a huge potential in 
clinical medicine.  However, our release system needs to be optimized before it can be 
applied in a clinical setting, including determining the adequate in vivo dose of FGF-2 
for human bone formation.  We believe that our system is one of the most promising 
methods that can be used to enhance bone formation.  
  
 
 
 
 
Conclusion 
       A specific FGF-2 concentration may be required for bone formation.  Our 
coating system can precisely release FGF-2 at concentrations adequate for inducing 
bone formation in vivo.  Because our system consists of approved medicine and 
solutions, it may have significant potential in clinical medicine. 
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Figure legends 
Table 1: Preparation of the solutions and agents used in this study.  All of the solutions 
and agents are approved for clinical usage in Japan. 
 
Figure 1: Three-dimensional views of the hydroxyapatite ceramic button (HAP-CB), 
which was made for cranial repair (cranioplasty) in rats.  Both sides of the HAP-CB 
were cut in order for bone formation to extend into the space around the bone defect. 
 
Figure 2: The HAP-CB implanted in the bone defects (burr holes).  The lower panel 
demonstrates how bone formation was measured.  Bone formation was quantified by 
measuring the length of the new bone extension into the inside of the bone defect and 
the thickness of the edges of the bone defect. 
 
Figure 3: SEM photos of the HAP-CB (A), FGF-L (B), FGF-H (C), and HAP-N (D).  
Particulate precipitations were observed on the HAP grains of the FGF-L (B), FGF-H 
(C), and HAP-N (D).  Magnification: 20000X. 
 Figure 4: Cell proliferation and bone morphogenetic protein-2 (BMP-2) expression are 
induced by fibroblastic growth factor-2 (FGF-2).  BHK-21 cells (fibroblasts) and 
MG-63 cells (osteoblasts) were incubated with increasing concentrations of FGF-2 for 
three days.  A) The number of BHK-21 cells after incubation with FGF-2.  B) The 
number of MG-63 cells after incubation with FGF-2.  C) Real-time PCR results of 
BMP-2 expression in BHK-21 cells (empty bars) and MG-63 cells (solid bars). BMP-2 
expression is indicated as fold increase (∆-∆ C(t)), in which the values normalized to 
GAPDH expression were compared with the BMP-2 expression in wells with 0 ng/mL 
of FGF-2.  The results shown are the average and standard deviation of three 
independent experiments.  * p <  0.05, **p < 0.01, ***p<0.001. 
 
Figure 5: FGF-2-release curves from the FGF-L (round) or FGF-H (square) buttons in 
phosphate-buffered saline.  The results shown are the average and standard deviation 
of three independent experiments.   
 
Figure 6: Cell proliferation and BMP-2 expression were stimulated by the HAP-N, 
FGF-L, and FGF-H buttons.  BHK-21 cells and MG-63 cells were incubated in 
medium including HAP-N, FGF-L, or FGF-H buttons for three days.  A) The number 
of BHK-21 cells after incubation with each of the three buttons.  B) The number of 
MG-63 cells after incubation with each of the three buttons.  C) Real-time PCR results 
of BMP-2 expression in BHK-21 cells (empty bars) and MG-63 cells (solid bars). 
BMP-2 expression is reported as fold increase (∆-∆ C(t)), in which values normalized to 
GAPDH expression were compared with the BMP-2 expression in HAP-N.  The 
results shown are the average and standard deviation of three independent experiments.  
* p < 0.05, **p < 0.01, ***p<0.001. 
 
Figure 7: Histological sections of the bone defects were stained with hematoxylin and 
eosin after demineralization.  The yellow dotted lines show the area of bone formation 
indicated by BF.  A) A representative section from Group 3 treated with FGF-L 
indicates the extension (arrows) of the bone formation into the open space left by the 
bone defect.  The lining cells in surroundings of bone formation seem osteoblasts.  B) 
A representative section from Group 3 indicates the bone formation (arrows) between 
the cranium and the dura membrane, resulting in increased cranial thickness.  C) A 
representative section from Group 1 treated with HAP-N, which shows the poor 
response of the bone formation under these conditions.  ILC: inner layer of the 
cranium.  Magnification: 100X.  
 
Figure 8: Bone formation was quantified in each group.  Group 1 was treated with the 
HAP-N button alone (cross lines), Group 2 with the HAP-N button and drips of the 
FGF-2 solution (triangle lines), Group 3 with the FGF-L button (square lines), and 
Group 4 with the FGF-H button (round lines).  A) The extension of new bone 
formation into the space left by the bone defect.  B) The increased thickness of the 
cranium due to the bone formation.  The results shown are the average and standard 
deviation of six samples.   * p < 0.01, **p < 0.001. 
 
Figure 9: The in vivo expression of BMP-2, alkaline phosphatase (ALP), and osteocalcin 
(OC) in the bone-defect tissues at two (empty bars) or four (solid bars) weeks after the 
procedure.  A) The expression of BMP-2.  B) The expression of ALP.  C) The 
expression of OC.  The gene expression is reported as fold increase (∆-C(t)), where the 
values were compared with GAPDH expression.  The results shown are the average 
and standard deviation of three samples.  * p < 0.05, **p <  0.01, ***p<0.001. 
